The FDA just expanded Mounjaro’s label to include reducing the risk of major adverse cardiovascular events, and the headline is easy to love and easy to misunderstand. We slow it down and translate what the approval actually means for people living with type 2 diabetes, especially those worried about heart attack, stroke, and cardiovascular death.

We unpack the exact endpoint behind the claim: MACE, which combines cardiovascular death, non-fatal heart attack, and non-fatal stroke, and we clarify what it is not saying (no, it is not “erasing plaque” or curing atherosclerotic cardiovascular disease). We also explain the real-world nuance around branding and indications: Mounjaro and Zepbound are both tirzepatide, but FDA labels are population-specific, and that can affect clinical decisions and insurance coverage.

Then we walk through the Surpass-CVOT cardiovascular outcomes trial in plain English. The key twist is the comparator: tirzepatide was tested against Trulicity (dulaglutide), an active GLP-1 medication with known heart benefit, not placebo. That’s why understanding noninferiority vs superiority matters so much. We talk hazard ratios, absolute vs relative risk, and the surprising finding that bigger weight loss and a larger A1C drop did not translate into statistically superior cardiovascular outcomes during the study window.

We close with practical guidance and a list of questions you can bring to your own checkup, including whether you have established cardiovascular disease, what makes you “high risk,” whether other cardioprotective meds are already doing the job, how dose changes could affect insulin or blood pressure meds, and what it will actually cost. If you found this helpful, subscribe, share the show with someone managing diabetes risk, and leave us a review so more people can find clear medical context.

Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

Support the show

Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

Artwork Rebrand and Avatars:

Vantage Design Works (Vanessa Jones)

Website: https://www.vantagedesignworks.com/

Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr

Original Artwork Concept: Olivia Pawlowski

Your lab portal lights up red and suddenly you are doing mental math on a creatinine value you have never thought about before. We get it and we see it all the time in clinic, so we built a clear guide to the three kidney tests that confuse people most: creatinine, eGFR (estimated glomerular filtration rate), and urine albumin or protein in the urine.

We start with what the kidneys actually do, down at the level of nephrons and glomeruli, then explain why creatinine is a helpful clue but not a perfect answer. Creatinine is measured, eGFR is estimated from that measurement plus factors like age and sex, and the two numbers typically move in opposite directions. From there, we tackle the big misconception: one low eGFR does not automatically mean chronic kidney disease. “Chronic” implies time, so we talk about why trends and prior labs matter, and how dehydration, acute illness, and certain medications can cause temporary changes that look scary on paper.

Then we add the missing piece many people never hear about: urine albumin testing. Protein leakage can signal kidney damage even when filtration looks relatively preserved, which is especially important for people with diabetes and hypertension. We wrap by sharing the questions we run through as clinicians so you can bring the right context to your next checkup.

Subscribe, share this with someone who reads labs at midnight, and please leave a quick review if it helps you feel more confident about your kidney numbers.

Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

Support the show

Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

Artwork Rebrand and Avatars:

Vantage Design Works (Vanessa Jones)

Website: https://www.vantagedesignworks.com/

Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr

Original Artwork Concept: Olivia Pawlowski

A single executive order can spark a thousand headlines, but it can’t conjure new evidence into existence. We dig into the recent move to change childhood vaccine recommendations in the United States and why the American Academy of Pediatrics is pushing back with the same blunt message: the science hasn’t changed. If you’re a parent hearing “maybe the schedule isn’t safe,” we unpack what that claim would require scientifically and why politics is not a substitute for data.

We also slow down on the parts that feel personal. Yes, it can look like “a lot of shots” when you’re staring at a baby’s thigh. But the number of syringes is not a measurement of immune overload. We talk through how the childhood immunization schedule is designed, what safety monitoring actually looks like, and why spacing vaccines out is not automatically safer. Delays create longer windows of vulnerability to measles, pertussis, and meningitis, and they add real burdens: more appointments, more missed work, more transportation stress, and more chances to fall behind.

Then we address the question that never seems to die: vaccines and autism. We explain what happened, why researchers investigated it so intensely, and what the large studies across millions of children consistently show. From there, we land on the bigger takeaway: skepticism has two responsibilities, questioning what we think we know and accepting the answer when the evidence becomes overwhelming.

If you want clear, evidence-based context from a family doctor and a nurse, hit play. Subscribe, share this with a parent who’s getting mixed messages, and leave a review so more people can find the show.

Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

Support the show

Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

Artwork Rebrand and Avatars:

Vantage Design Works (Vanessa Jones)

Website: https://www.vantagedesignworks.com/

Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr

Original Artwork Concept: Olivia Pawlowski